CN117085174A - 用于医美术后创面护理的液体敷料及其制备方法 - Google Patents
用于医美术后创面护理的液体敷料及其制备方法 Download PDFInfo
- Publication number
- CN117085174A CN117085174A CN202311060171.9A CN202311060171A CN117085174A CN 117085174 A CN117085174 A CN 117085174A CN 202311060171 A CN202311060171 A CN 202311060171A CN 117085174 A CN117085174 A CN 117085174A
- Authority
- CN
- China
- Prior art keywords
- medical
- liquid dressing
- artistic
- wound care
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 30
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 30
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 30
- 239000011734 sodium Substances 0.000 claims abstract description 30
- 239000002346 layers by function Substances 0.000 claims abstract description 27
- 239000010410 layer Substances 0.000 claims abstract description 26
- 230000009182 swimming Effects 0.000 claims abstract description 25
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 19
- 239000000499 gel Substances 0.000 claims abstract description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 19
- 241000237536 Mytilus edulis Species 0.000 claims abstract description 16
- 235000020638 mussel Nutrition 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 14
- 108010010803 Gelatin Proteins 0.000 claims abstract description 12
- 239000008273 gelatin Substances 0.000 claims abstract description 12
- 229920000159 gelatin Polymers 0.000 claims abstract description 12
- 235000019322 gelatine Nutrition 0.000 claims abstract description 12
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 12
- 229920001971 elastomer Polymers 0.000 claims abstract description 11
- 239000000806 elastomer Substances 0.000 claims abstract description 11
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract description 10
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 19
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 13
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 9
- 229910052740 iodine Inorganic materials 0.000 claims description 9
- 239000011630 iodine Substances 0.000 claims description 9
- 239000007853 buffer solution Substances 0.000 claims description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 7
- 239000003431 cross linking reagent Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 235000010413 sodium alginate Nutrition 0.000 claims description 7
- 239000000661 sodium alginate Substances 0.000 claims description 7
- 229940005550 sodium alginate Drugs 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 239000012190 activator Substances 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- HPILSDOMLLYBQF-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COC(CCC)OCC1CO1 HPILSDOMLLYBQF-UHFFFAOYSA-N 0.000 claims description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 3
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 claims description 3
- 238000007605 air drying Methods 0.000 claims description 3
- 150000001718 carbodiimides Chemical class 0.000 claims description 3
- 239000012304 carboxyl activating agent Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 230000000474 nursing effect Effects 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 abstract description 42
- 206010052428 Wound Diseases 0.000 abstract description 41
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 13
- 230000029663 wound healing Effects 0.000 abstract description 8
- 230000003020 moisturizing effect Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 abstract 1
- 230000035699 permeability Effects 0.000 description 8
- -1 Glycerol glucoside Chemical class 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 5
- 229920002379 silicone rubber Polymers 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229930182478 glucoside Natural products 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000002390 adhesive tape Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000007981 phosphate-citrate buffer Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0038—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/106—Halogens or compounds thereof, e.g. iodine, chlorite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于医疗器械领域,具体涉及一种用于医美术后创面护理的液体敷料及其制备方法。一种用于医美术后创面护理的液体敷料包括基底层和功能层;所述基底层包括组分聚乙二醇碘、羧氨基葡聚多糖钠、明胶;功能层包括组分鱼鳔‑海藻酸钠‑透明质酸复合物、抗菌肽、贻贝粘蛋白、甘油葡糖苷、载体型糖苷硅氧烷弹性体凝胶。本发明的制成的液体敷料具有促进伤口愈合、保湿效果好、抗菌功能强、舒适性和黏附性高以及良好的生物相容性等优势。它们能够为伤口提供有效的治疗和保护,加速伤口愈合过程,并提供良好的治疗体验。
Description
技术领域
本发明属于医疗器械领域,具体涉及用于医美术后创面护理的液体敷料及其制备方法。
背景技术
皮肤作为人体最大的器官之一,在保护皮下组织免受外界有害因素侵袭、维持内环境稳态、保证机体正常生理功能顺利运转等方面发挥着巨大的作用。
医疗美容(Medical Cosmetology)是指运用药物、手术、医疗器械以及其他具有创伤性或者不可逆性的医学技术方法对人的容貌和人体各部位形态进行的修复与再塑的美容方式。在医疗美容后会具有一段修复期,此时皮肤处于损伤状态;皮肤极为敏感且无法起到正常的屏障作用,所以一般需要使用封闭性的敷料帮助修复和隔绝外界刺激。
但目前的不含无纺布的凝胶状液态辅料存在质地太坚韧不服帖、抗菌能力稍弱、液体吸收能力不足等问题,具有进一步改进的空间。
发明内容
本发明的目的在于提供一种用于医美术后创面护理的液体敷料,能够有效抗菌、帮助皮肤修复和吸收组织液;且肤感舒适。
一种用于医美术后创面护理的液体敷料,包括基底层和功能层;
所述基底层以质量份计包括以下组分:
聚乙二醇碘 3-10
羧氨基葡聚多糖钠 0.5-5
明胶 0.5-5
所述明胶和羧氨基葡聚多糖钠的总质量份≥4;
所述功能层以质量份计包括以下组分:
鱼鳔提取物、海藻酸钠、透明质酸的质量比为1:10-20:10-20。
特别地,所述鱼鳔-海藻酸钠-透明质酸复合物的制备方法包括步骤:
(1)将鱼鳔提取物、海藻酸钠、透明质酸溶于水中,得到溶液1;
(2)将交联剂加入所述溶液1中,并用缓冲溶液调节pH值为4.0-5.5,得到溶液2;
(3)向所述溶液2中加入羧基激活剂并搅拌,搅拌过程中利用缓冲溶液控制溶液2的pH处于2.0-5.5范围内;直到不再生成凝胶状物质,得鱼鳔-海藻酸钠-透明质酸复合物。
特别地,所述交联剂为以下的至少一种:
丁二醇二缩水甘油醚、己二酸二酰肼、聚乙二醇;
所述交联剂的用量为溶液1的0.3-0.6g/100ml。
特别地,所述羧基激活剂为以下的至少一种:
N,N,N”,N”-四甲基乙二胺、N-羟基琥珀酰亚胺、碳化二亚胺;
所述羧基激活剂的用量为溶液2的0.2-0.4g/100ml。
缓冲溶液为以下的至少一种:
磷酸盐缓冲溶液,柠檬酸盐缓冲溶液和醋酸盐缓冲溶液。
特别地,所述透明质酸的重均分子量MW≥2000kda。
特别地,所述基底层以质量份计包括以下组分:
聚乙二醇碘 8
羧氨基葡聚多糖钠 3.4
明胶 1.2;
所述功能层以质量份计包括以下组分:
前述用于医美术后创面护理的液体敷料的制备方法,包括以下步骤:
(1)将基底层和功能层放入水中,施加压力使其复合,得液体辅料1;
(2)取出复合后的液体辅料1,冻干或低温风干至预定含水量后,得用于医美术后创面护理的液体敷料;
所述基底层的制备方法包括步骤:
将聚乙二醇碘、羧氨基葡聚多糖钠、明胶溶解于水中;然后取出脱水至恒干后备用;
所述功能层的制备方法包括步骤:
(1)将抗菌肽、贻贝粘蛋白、甘油葡糖苷、载体型糖苷硅氧烷弹性体凝胶与适量水混合形成乳液;
(2)将冻干后的鱼鳔-海藻酸钠-透明质酸复合物浸润在乳液中;然后再次冻干,备用。
本发明的基底层主要用于外界隔绝,保持内部功能层的稳定和发挥修复皮肤的作用。
本发明的功能层是与皮肤创面直接接触的层面,为了发挥应有的作用,最后制备的功能层厚度至少要保证有3mm;而基底层处于外界和功能层之间,只负责隔绝和辅助功能层的定型,厚度在0.5mm以上即可正常发挥作用。
本发明基底层中:聚乙二醇、羧氨基葡聚多糖钠和明胶都可独自制成水凝胶,但本发明发现,无论是单一的聚乙二醇、羧氨基葡聚多糖钠或是聚乙二醇、羧氨基葡聚多糖钠的混合,形成的水凝胶韧性不足,容易碎裂;所以需要加入一定量的明胶增强韧性。
而为了起到杀菌的作用,将聚乙二醇与碘交联形成聚乙二醇碘;聚乙二醇碘具有广谱抗菌作用,可以有效抵抗细菌、真菌和病毒等微生物的感染;具有较好的渗透性和持久性,能够提供长时间的抗菌保护。但是聚乙二醇碘对受损皮肤的刺激性较大,在皮肤创面上可能会加重不适。所以在本发明中仅作为基底层材料使用。
本发明中功能层各成分的作用:
鱼鳔提取物:具有高含量的胶原蛋白、多肽等氨基酸类成分,具有促进伤口愈合的效果。
海藻酸钠:具有良好的保湿性和吸附性;可以形成一层保护膜,保持伤口的湿润环境,促进创面愈合和缓解疼痛。
透明质酸:透明质酸的用途根据分子量有很大差别,本发明使用的是重均分子量MW≥2000kda,起到的是保持功能层形态稳定、容纳其他成分、吸收组织液。保湿的效果。
抗菌肽:具有广谱的抗菌活性,可以杀灭或抑制细菌、真菌、病毒等微生物的生长;可以增强创面的防御能力,预防或治疗感染。
贻贝粘蛋白:具有很强的粘附力和生物相容性;本发明中主要作为生物胶水使用,将敷料中的各种成分和吸收的组织液锁在辅料内部防止溢出,保持创面湿润和稳定;同时贻贝粘蛋白还具有减少瘢痕、缓解瘙痒的作用。(贻贝粘蛋白治疗烧伤后瘙痒的临床观察,虞俊杰等,《中华损伤与修复杂志(电子版)》2015年01期)。
甘油葡糖苷:这是一种天然存在于软骨、皮肤、结缔组织等部位的多糖类物质,具有保湿、抗炎、抗氧化等作用;可以改善创面的微循环,增加营养供应,促进细胞增殖和分化,加速伤口愈合。
载体型糖苷硅氧烷弹性体凝胶:这是一种由糖苷硅氧烷和弹性体复合而成的载体材料,具有高透气性、高弹性、低粘附性和低刺激性;可以适应不同形状和大小的创面,保持创面湿润,避免敷料与创面粘连,减轻更换敷料时的疼痛。
本发明的鱼鳔-海藻酸钠-透明质酸复合物在复合后具有优异的空间结构,能够吸收大量的水分以及其他的有效成分作为载体;同时还具有高生物相容性,可以形成一层凝胶状的保护层,保持创面湿润;还能吸收渗出的组织液。
载体型糖苷硅氧烷弹性体凝胶主要是用于调节肤感和辅助载体的作用;同时还具有良好的保湿效果;另外相比于其他的凝胶类物质还具有自乳化效果,使得本发明配方不需要额外添加乳化剂。
医美后敷料的要求有以下几个方面:
稳定的愈合环境:医疗用敷料应该创造一个良好的封闭环境,保持局部湿润并防止外界细菌感染、磨擦等物理损伤;同时还需要具有一定的透气性。
吸收排液:医疗用敷料应该能够吸收伤口分泌的液体,例如血液、浆液或渗出液。
一定的渗透性:敷料应该能够允许氧气和水蒸气的渗透,以促进氧气供应和湿润环境。
可变形性:敷料应该具备柔软性、适合性和延展性,以便能够贴合伤口的形状,并适应伤口周围的移动和变化;以及易于剪裁、适应不同大小和形状的伤口,并且能够提供简单而有效的固定。
无毒和无过敏性:医疗用敷料应该是无毒的,并且不会引起过敏反应。
本发明中主要依靠贻贝粘蛋白保持创面和功能层的紧密贴合,然而贻贝粘蛋白的紧密贴合并不会影响创面的透气性和排出代谢废物,贻贝粘蛋白是一种多孔性的材料,具有良好的渗透性;同时功能层的主体材料鱼鳔-海藻酸钠-透明质酸复合物和载体型糖苷硅氧烷弹性体凝胶也具有良好的渗透性。
本发明的防止细菌感染主要依靠抗菌肽完成,而处于最外侧的基底层也能起到隔绝的作用。
本发明的鱼鳔-海藻酸钠-透明质酸复合物和载体型糖苷硅氧烷弹性体凝胶都能起到吸收排出液的效果。
本发明中贻贝粘蛋白的强粘附力和载体型糖苷硅氧烷弹性体凝胶的低粘附性看似矛盾,但其实所指的不是同一个问题。
载体型糖苷硅氧烷弹性体凝胶的低粘附性是指敷料与创面之间的粘附力较小,不容易产生粘连,在剥离时可以减少创面的损伤,保护新生的肉芽组织,减轻更换敷料时的疼痛。
而贻贝粘蛋白的强粘附力是指由于敷料具有一定的形变能力,使得辅料可以自适应创面的形状进行贴合,使得两者间不存在空隙;使得敷料吸收的组织液锁在敷料内,同时防止细菌和异物的侵入,促进伤口愈合。
本发明的“低粘附性”主要体现在敷料与创面之间的接触面积上,而“粘附力”主要体现在敷料与创面之外的边缘部分上。这样,既可以保证敷料与创面之间的温和接触,又可以保证敷料与创面之外的紧密结合。可以与静电胶布等其他领域的胶黏用途物品进行类比,静电胶布就是典型的强粘附力(可以通过静电力吸附微小物体)低粘附性(容易剥离)物体。
本发明的有益效果:
(1)本发明制成的敷料为凝胶状的液体敷料;不需要无纺布等支架物质的制成,使得具有良好的变形性,能够紧密贴合创面;且可以根据创面大小进行裁剪。
(2)本发明的制成的液体敷料具有促进伤口愈合、保湿效果好、抗菌功能强、舒适性和黏附性高以及良好的生物相容性等优势。它们能够为伤口提供有效的治疗和保护,加速伤口愈合过程,并提供良好的治疗体验。
具体实施方式
下面结合具体实施例,对本发明作进一步详细的阐述,下述实施例不用于限制本发明,仅用于说明本发明。以下实施例中所使用的实验方法如无特殊说明,实施例中未注明具体条件的实验方法,通常按照常规条件,下述实施例中所使用的材料、试剂等,如无特殊说明,均可从商业途径得到。
本发明中部分原材料的来源:
鱼鳔提取物:陕西沐菲生物科技有限公司。
抗菌肽:抗菌肽LZ1 peptide,西安冠茂生物科技有限公司。
透明质酸:高分子透明质酸,华熙生物,MW=2000kda。
载体型糖苷硅氧烷弹性体凝胶:广州标美药用辅料有限公司。
贻贝粘蛋白:山西游辰生物科技有限公司。
鱼鳔-海藻酸钠-透明质酸复合物的制备,包括以下步骤:
(1)将鱼鳔提取物、海藻酸钠、透明质酸溶于水中,得到溶液1;使得鱼鳔提取物、海藻酸钠、透明质酸的总浓度达到1.5%(g/100ml);
(2)将交联剂加入所述溶液1中,并用缓冲溶液调节pH值,得到溶液2;
缓冲溶液为以下的至少一种:
磷酸盐缓冲溶液,柠檬酸盐缓冲溶液和醋酸盐缓冲溶液。
(3)向所述溶液2中加入羧基激活剂并搅拌,搅拌过程中利用缓冲溶液控制溶液2的pH处于2.0-5.5范围内;直到不再生成凝胶状物质,得鱼鳔-海藻酸钠-透明质酸复合物;捞出后冻干备用。
其中的技术参数如下表1中显示。
表1
表1中,丁二醇二缩水甘油醚、己二酸二酰肼、聚乙二醇的用量是以溶液1计算;N,N,N”,N”-四甲基乙二胺、N-羟基琥珀酰亚胺、碳化二亚胺的用量是以溶液2计算;空白表示没有添加。
功能层的制备,包括以下步骤:
(1)将抗菌肽、贻贝粘蛋白、甘油葡糖苷、载体型糖苷硅氧烷弹性体凝胶与适量水混合形成乳液;
(2)将冻干后的鱼鳔-海藻酸钠-透明质酸复合物浸润在乳液中;然后再次冻干,备用。
其中的技术参数如下表2中显示。
表2
序号 | 4 | 5 | 6 | D-1 | D-2 | D-3 |
鱼鳔-海藻酸钠-透明质酸复合物(质量份) | 5 | 8 | 8 | 1 | 8 | 8 |
鱼鳔-海藻酸钠-透明质酸复合物(序号) | 1 | 2 | 3 | 1 | 1 | 1 |
抗菌肽(质量份) | 0.01 | 0.02 | 0.03 | 0.02 | 0 | 0.02 |
贻贝粘蛋白(质量份) | 0.2 | 1.4 | 2.0 | 1.4 | 1.4 | 0 |
甘油葡糖苷(质量份) | 2 | 4 | 6 | 4 | 4 | 4 |
载体型糖苷硅氧烷弹性体凝胶(质量份) | 0.5 | 1.8 | 2.0 | 8.8 | 1.8 | 3.2 |
基底层的制备,包括以下步骤:
(1)将聚乙二醇碘、羧氨基葡聚多糖钠、明胶溶解于水中;然后取出脱水至恒干后备用;
其中的技术参数如下表3中显示。
表3
用于医美术后创面护理的液体敷料,包括以下步骤:
(1)将基底层和功能层放入水中,施加压力使其复合,得液体辅料1;
(2)取出复合后的液体辅料1,冻干或低温风干至预定含水量后,得用于医美术后创面护理的液体敷料;
其中的技术参数如下表4中显示。
表4
序号 | A | B | C | F-1 | F-2 | F-3 |
基底层序号 | 7 | 8 | 9 | 7 | 7 | 7 |
基底层厚度,mm | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
功能层序号 | 4 | 5 | 6 | D-1 | D-2 | D-3 |
功能层厚度,mm | 3 | 3 | 3 | 3 | 3 | 3 |
成品含水量,% | 90 | 90 | 90 | 90 | 90 | 90 |
对制得的医美术后创面护理的液体敷料进行测试,具体测试方法和结果为:
透气性的检测方法:参考YY/T0471.1-2004《接触性创面敷料试验方法第1部分:液体吸收性》的相关内容,具体检测水蒸气接触抗菌敷料的水蒸气透过率。
抗菌性能的检测方法:参考GB/T20944.3-2008《纺织品抗菌性能的评价第3部分:振荡法》的相关内容;
生物相容性的检测方法:参考GB/T16886.5-2017《医疗器械生物学评价第5部分:体外细胞毒性试验》中MTT法的相关内容。
液体吸收量测试:参考YY/T 0471-2004《接触性创面敷料试验方法》。
拉伸性能检测方法:将材料剪成75×15mm的长方形,在室温,湿度60%条件下用厚度仪测其厚度,然后使用万能材料实验机测定其拉伸力学性能,设定参数如下:拉伸速度为10mm/min,夹持距离为65mm,样品宽度为15mm。拉伸断裂强度由公式进行计算。式中F(N)为试样断裂时的负荷,b(mm)、d(mm)分别为样品宽度与厚度.
剥离强度检测方法:参考YY/T 0148-2006《医用胶带通用要求》。
持粘力测试:参考GB/T 4851-2014《胶粘带持粘性试验方法》。
结果如下表5所示
表5
项目/序号 | A | B | C | F-1 | F-2 | F-3 |
水蒸气透过率,g/(m2·24h) | 3897 | 3971 | 3772 | 2106 | 3726 | 2980 |
金黄色葡萄球菌抑菌率,% | 99.6 | 99.7 | 99.9 | 99.7 | 75.4 | 99.7 |
大肠杆菌抑菌率,% | 99.5 | 99.5 | 99.6 | 99.5 | 88.1 | 99.5 |
白色念珠菌抑菌率,% | 98.2 | 98.4 | 98.6 | 98.5 | 79.6 | 98.4 |
细胞相对存活率,% | 99.3 | 99.5 | 99.3 | 99.4 | 99.5 | 99.4 |
细胞毒性等级 | 0 | 0 | 0 | 0 | 0 | 0 |
液体吸收量,g/(m2·24h) | 8694 | 9106 | 8862 | 4831 | 8771 | 6852 |
拉伸强度(Mpa) | 0.85 | 0.76 | 0.54 | 0.95 | 0.92 | 1.11 |
断裂伸长率(%) | 19.32 | 23.21 | 16.32 | 18.21 | 19.11 | 18.75 |
剥离强度(N/CM) | 1.32 | 1.18 | 1.09 | 0.55 | 1.17 | 0.91 |
持粘力(不下滑时间,min) | 30 | 30 | 30 | / | 30 | 10 |
剥离强度随着载体型糖苷硅氧烷弹性体凝胶含量增加而下降;对比例F-1和F-3由于添加过量的载体型糖苷硅氧烷弹性体凝胶导致持粘力测试无法得到有效的实验数据和过低的剥离强度。较低的拉伸强度和较高的断裂伸长率证明本发明的可变形性较高,能够贴合伤口。
本发明中,拉伸强度、断裂伸长率和剥离强度主要的影响因素包括鱼鳔-海藻酸钠-透明质酸复合物、贻贝粘蛋白、载体型糖苷硅氧烷弹性体凝胶和基底层各成分的含量。
对比例F-2显示,不添加抗菌肽的情况下会导致抑菌率大幅下降,但是由于聚乙二醇碘具有抗菌效果,所以保留了一定的抗菌性。
本发明具有优越的水蒸气透过率和液体吸收量;对比例D-1由于缺少鱼鳔-海藻酸钠-透明质酸复合物的作为主体材料,导致水蒸气透过率和液体吸收量严重下降;而D-3缺少贻贝粘蛋白,也导致水蒸气透过率和液体吸收量的下降。
最后应当说明的是,以上内容仅用以说明本发明的技术方案,而非对本发明保护范围的限制,本领域的普通技术人员对本发明的技术方案进行的简单修改或者等同替换,均不脱离本发明技术方案的实质和范围。
Claims (8)
1.用于医美术后创面护理的液体敷料,其特征在于,包括基底层和功能层;
所述基底层以质量份计包括以下组分:
聚乙二醇碘3-10
羧氨基葡聚多糖钠0.5-5
明胶0.5-5
所述明胶和羧氨基葡聚多糖钠的总质量份≥4;
所述功能层以质量份计包括以下组分:
鱼鳔提取物、海藻酸钠、透明质酸的质量比为1:10-20:10-20。
2.根据权利要求1所述的用于医美术后创面护理的液体敷料,其特征在于,所述鱼鳔-海藻酸钠-透明质酸复合物的制备方法包括步骤:
(1)将鱼鳔提取物、海藻酸钠、透明质酸溶于水中,得到溶液1;
(2)将交联剂加入所述溶液1中,并用缓冲溶液调节pH值为4.0-5.5,得到溶液2;
(3)向所述溶液2中加入羧基激活剂并搅拌,搅拌过程中利用缓冲溶液控制溶液2的pH处于2.0-5.5范围内;直到不再生成凝胶状物质,得鱼鳔-海藻酸钠-透明质酸复合物。
3.根据权利要求2所述的用于医美术后创面护理的液体敷料,其特征在于,所述交联剂为以下的至少一种:
丁二醇二缩水甘油醚、己二酸二酰肼、聚乙二醇;
所述交联剂的用量为溶液1的0.3-0.6g/100ml。
4.根据权利要求2所述的用于医美术后创面护理的液体敷料,其特征在于,所述羧基激活剂为以下的至少一种:
N,N,N”,N”-四甲基乙二胺、N-羟基琥珀酰亚胺、碳化二亚胺;
所述羧基激活剂的用量为溶液2的0.2-0.4g/100ml。
5.根据权利要求1所述的用于医美术后创面护理的液体敷料,其特征在于,所述透明质酸的重均分子量MW≥2000kda。
6.根据权利要求1-5任一所述的用于医美术后创面护理的液体敷料,其特征在于,所述基底层以质量份计包括以下组分:
聚乙二醇碘8
羧氨基葡聚多糖钠3.4
明胶1.2。
7.根据权利要求1-5任一所述的用于医美术后创面护理的液体敷料,其特征在于,所述功能层以质量份计包括以下组分:
8.权利要求1-7任一所述的用于医美术后创面护理的液体敷料的制备方法,其特征在于,包括以下步骤:
(1)将基底层和功能层放入水中,施加压力使其复合,得液体辅料1;
(2)取出复合后的液体辅料1,冻干或低温风干至预定含水量后,得用于医美术后创面护理的液体敷料;
所述基底层的制备方法包括步骤:
将聚乙二醇碘、羧氨基葡聚多糖钠、明胶溶解于水中;然后取出脱水至恒干后备用;
所述功能层的制备方法包括步骤:
(1)将抗菌肽、贻贝粘蛋白、甘油葡糖苷、载体型糖苷硅氧烷弹性体凝胶与适量水混合形成乳液;
(2)将冻干后的鱼鳔-海藻酸钠-透明质酸复合物浸润在乳液中;然后再次冻干,备用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311060171.9A CN117085174B (zh) | 2023-08-22 | 2023-08-22 | 用于医美术后创面护理的液体敷料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311060171.9A CN117085174B (zh) | 2023-08-22 | 2023-08-22 | 用于医美术后创面护理的液体敷料及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117085174A true CN117085174A (zh) | 2023-11-21 |
CN117085174B CN117085174B (zh) | 2024-02-06 |
Family
ID=88773135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311060171.9A Active CN117085174B (zh) | 2023-08-22 | 2023-08-22 | 用于医美术后创面护理的液体敷料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117085174B (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060293277A1 (en) * | 2005-06-27 | 2006-12-28 | Leshchiner Adelya K | Cross-linked gels of hyaluronic acid with hydrophobic polymers and processes for making for making them |
CN103755981A (zh) * | 2014-01-14 | 2014-04-30 | 西北大学 | 一种用作皮肤填充材料的水凝胶及其制备方法 |
CN104130434A (zh) * | 2013-05-02 | 2014-11-05 | 3M创新有限公司 | 水胶体敷料及其制备方法 |
CN105343926A (zh) * | 2015-11-09 | 2016-02-24 | 广东泰宝医疗科技股份有限公司 | 一种含有纳米二氧化硅的疤痕贴及其制备方法 |
WO2017101020A1 (zh) * | 2015-12-15 | 2017-06-22 | 江阴市本特塞缪森生命科学研究院有限公司 | 一种改良的敷料 |
KR101780392B1 (ko) * | 2017-02-17 | 2017-09-21 | 주식회사 케이티에이치아시아 | 순수 하이드로겔에 고무의 특성을 접합시켜 밀착성과 보습감, 강도를 보다 더 향상시킨 하이드로겔 제조방법 |
CN108014366A (zh) * | 2017-12-15 | 2018-05-11 | 青岛海洋生物医药研究院 | 一种海洋生物材料复合水凝胶敷料及其制备方法 |
CN114699508A (zh) * | 2022-04-12 | 2022-07-05 | 南京天朗制药有限公司 | 一种硅酮凝胶及其制备方法和应用 |
CN115569232A (zh) * | 2022-10-31 | 2023-01-06 | 湖北三江航天江河化工科技有限公司 | 双层水凝胶敷料及其制备方法和应用 |
-
2023
- 2023-08-22 CN CN202311060171.9A patent/CN117085174B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060293277A1 (en) * | 2005-06-27 | 2006-12-28 | Leshchiner Adelya K | Cross-linked gels of hyaluronic acid with hydrophobic polymers and processes for making for making them |
CN104130434A (zh) * | 2013-05-02 | 2014-11-05 | 3M创新有限公司 | 水胶体敷料及其制备方法 |
CN103755981A (zh) * | 2014-01-14 | 2014-04-30 | 西北大学 | 一种用作皮肤填充材料的水凝胶及其制备方法 |
CN105343926A (zh) * | 2015-11-09 | 2016-02-24 | 广东泰宝医疗科技股份有限公司 | 一种含有纳米二氧化硅的疤痕贴及其制备方法 |
WO2017101020A1 (zh) * | 2015-12-15 | 2017-06-22 | 江阴市本特塞缪森生命科学研究院有限公司 | 一种改良的敷料 |
KR101780392B1 (ko) * | 2017-02-17 | 2017-09-21 | 주식회사 케이티에이치아시아 | 순수 하이드로겔에 고무의 특성을 접합시켜 밀착성과 보습감, 강도를 보다 더 향상시킨 하이드로겔 제조방법 |
CN108014366A (zh) * | 2017-12-15 | 2018-05-11 | 青岛海洋生物医药研究院 | 一种海洋生物材料复合水凝胶敷料及其制备方法 |
CN114699508A (zh) * | 2022-04-12 | 2022-07-05 | 南京天朗制药有限公司 | 一种硅酮凝胶及其制备方法和应用 |
CN115569232A (zh) * | 2022-10-31 | 2023-01-06 | 湖北三江航天江河化工科技有限公司 | 双层水凝胶敷料及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN117085174B (zh) | 2024-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108014366B (zh) | 一种海洋生物材料复合水凝胶敷料及其制备方法 | |
Nguyen et al. | Biomedical materials for wound dressing: Recent advances and applications | |
Lei et al. | Optimization of human-like collagen composite polysaccharide hydrogel dressing preparation using response surface for burn repair | |
EP3659631B1 (en) | Wound dressing comprising hyaluronic acid-calcium and polylysine and manufacturing method therefor | |
ES2416458T3 (es) | Materiales para vendajes | |
US6635272B2 (en) | Wound dressing and drug delivery system | |
Shyna et al. | A nonadherent chitosan-polyvinyl alcohol absorbent wound dressing prepared via controlled freeze-dry technology | |
ES2373676T3 (es) | Vendajes para heridas que comprenden celulosa oxidada y colágeno recombinante humano. | |
US20190151495A1 (en) | Composite biomaterials with controlled release of active ingredient, preparation process and uses | |
US7709021B2 (en) | Microbial cellulose wound dressing for treating chronic wounds | |
CN110507845A (zh) | 生物复合透气敷料及其制备方法 | |
Valipour et al. | Preparation and characterization of wound healing hydrogel based on fish skin collagen and chitosan cross-linked by dialdehyde starch | |
Thomas | A review of the physical, biological and clinical properties of a bacterial cellulose wound | |
WO2017101020A1 (zh) | 一种改良的敷料 | |
US20050181025A1 (en) | Preparation for wound healing and prevention of bandage adhesion to the wound | |
CN112891615B (zh) | 一种液体创口贴及其制备方法 | |
CN117085174B (zh) | 用于医美术后创面护理的液体敷料及其制备方法 | |
Tan et al. | Comparing DuoDERM ER with scarlet red in the treatment of split skin graft donor sites | |
CN106139229A (zh) | 一种新型抗菌水凝胶敷料及其制备方法 | |
CN115887747B (zh) | 一种含有纳米孔隙柔性膜的液体创口保护材料及其制备方法 | |
RU2582220C1 (ru) | Повязка для лечения ран на основе хитозана | |
WO2003090640A2 (en) | Microbial cellulose wound dressing for treating chronic wounds | |
Imran et al. | Tualang honey hydrogel in the treatment of split-skin graft donor sites | |
CN111012944A (zh) | 一种基于藻酸盐和透明质酸的液体敷料及其制备方法 | |
Thomas | Vapour-permeable film dressings |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |